全文获取类型
收费全文 | 21631篇 |
免费 | 1473篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 129篇 |
儿科学 | 470篇 |
妇产科学 | 307篇 |
基础医学 | 2815篇 |
口腔科学 | 334篇 |
临床医学 | 2713篇 |
内科学 | 3698篇 |
皮肤病学 | 205篇 |
神经病学 | 1956篇 |
特种医学 | 768篇 |
外科学 | 3160篇 |
综合类 | 297篇 |
一般理论 | 29篇 |
预防医学 | 2748篇 |
眼科学 | 432篇 |
药学 | 1695篇 |
中国医学 | 35篇 |
肿瘤学 | 1370篇 |
出版年
2024年 | 15篇 |
2023年 | 130篇 |
2022年 | 194篇 |
2021年 | 515篇 |
2020年 | 325篇 |
2019年 | 473篇 |
2018年 | 548篇 |
2017年 | 426篇 |
2016年 | 454篇 |
2015年 | 616篇 |
2014年 | 797篇 |
2013年 | 1032篇 |
2012年 | 1728篇 |
2011年 | 1731篇 |
2010年 | 987篇 |
2009年 | 924篇 |
2008年 | 1523篇 |
2007年 | 1668篇 |
2006年 | 1502篇 |
2005年 | 1495篇 |
2004年 | 1451篇 |
2003年 | 1369篇 |
2002年 | 1189篇 |
2001年 | 182篇 |
2000年 | 135篇 |
1999年 | 186篇 |
1998年 | 239篇 |
1997年 | 160篇 |
1996年 | 139篇 |
1995年 | 113篇 |
1994年 | 115篇 |
1993年 | 96篇 |
1992年 | 64篇 |
1991年 | 56篇 |
1990年 | 48篇 |
1989年 | 53篇 |
1988年 | 44篇 |
1987年 | 46篇 |
1986年 | 38篇 |
1985年 | 38篇 |
1984年 | 34篇 |
1983年 | 38篇 |
1982年 | 31篇 |
1981年 | 29篇 |
1980年 | 28篇 |
1979年 | 11篇 |
1978年 | 14篇 |
1977年 | 16篇 |
1976年 | 19篇 |
1970年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
J. O’Byrne S. Eustace M. M. Stephens M. N. M. R. Farahat G. Yanni R. Posten G. S. Panayi S. Sant R. Costello M. Barry J. Hassan C. Feighery B. Bresnihan A. Whelan F. Coakley A. M. de Paor R. B. Reilly E. B. Casey V. J. Tormey G. Kearns K. Gaffney P. J. Freyne M. Callaghan O. FitzGerald D. Veale E. O’Nuallain D. Reen D. Veale M. Farrell O. FitzGerald S. Rogers L. Barnes R. J. Coughlan C. McCarthy M. McDermott D. Hourihane C. O'Morain S. O'Reilly P. Hartley E. Casey L. Clancy F. Mulcahy N. Hall A. Murphy C. Breen D. Kelleher M. Abuzakouk C. O'Farrelly 《Irish journal of medical science》1992,161(6):438-442
34.
P M Franz S L Anliker J T Callaghan K A DeSante P H Dhahir R L Nelson A Rubin 《Drug metabolism and disposition》1990,18(6):968-973
Racemic picenadol is being tested clinically as an analgesic. The (+)-enantiomer of picenadol is an opioid agonist and the (-)-enantiomer is a weak agonist/antagonist. The disposition of racemic [14C] picenadol was studied in healthy men after a single dose was administered im (N = 3) and orally (N = 5). After the dose, virtually none of the radioactivity that appeared in blood was associated with the red cells. In plasma, approximately 4% of the radioactivity was attributable to the parent drug, the remainder being picenadol glucuronide (approximately 35%) and other metabolites. The t1/2 for total radioactivity was 6 hr, that for the unchanged drug was 3.5 hr. Picenadol was present in plasma almost exclusively as the (+)-enantiomer. However, after incubation with glucuronidase and sulfatase, plasma contained 2 to 4 times more (-)- than (+)-picenadol, indicating that more conjugated (-)-picenadol than conjugated (+)-picenadol was in the plasma. After im and oral administration of [14C]picenadol, plasma levels of radioactivity were generally 10 and 70 times higher than those in saliva, respectively. More than 90% of the administered radioactivity was excreted in the urine, mostly as picendol glucuronide, and lesser amounts of picenadol sulfate and N-desmethylpicenadol sulfate. Only about 1% of the administered dose of picenadol appeared unchanged in urine. The disposition of racemic picenadol in humans was stereoselective, the (-)-picenadol apparently being metabolized preferentially over the (+)-enantiomer. This finding was of particular interest in view of the dissimilar pharmacologic activities of the enantiomers.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
35.
Lamiya Samad Chris Hollis Martin Prince Robert Goodman 《International journal of methods in psychiatric research》2005,14(4):230-230
The original article to which this Erratum refers was published in International Journal of Methods in Psychiatric Research, 2005; Vol.14, No.3, 158–166. Copyright © 2005 John Wiley & Sons, Ltd. 相似文献
36.
Diego A Preciado Louise Lawson Colm Madden David Myer Chris Ngo John K Bradshaw Daniel I Choo John H Greinwald 《Otology & neurotology》2005,26(4):610-615
OBJECTIVES: To determine whether a stepwise diagnostic paradigm is more diagnostically efficient and cost-effective than a simultaneous testing approach in the evaluation of idiopathic pediatric sensorineural hearing loss (SNHL). DESIGN: Prospective prevalence study. SETTING: Tertiary referral children's hospital. PATIENTS: Consecutive children (n = 150) presenting with idiopathic SNHL in the last 2 years. INTERVENTIONS: All children were evaluated with full diagnostic evaluations including GJB2 screens, temporal bone computed tomography scans, and laboratory investigations. MAIN OUTCOME MEASURES: 1) Diagnostic yields of GJB2 screens, imaging, and laboratory results per SNHL category; 2) Cost analysis comparing a sequential versus a simultaneous testing approach. RESULTS: Overall, 12.0% of patients had biallelic mutations in the GJB2 gene, whereas 30% of patients had an abnormality on temporal bone scan. Laboratory testing did not reveal the SNHL etiology in any patient. While maintaining diagnostic accuracy, significant cost savings were inferred by using a sequential diagnostic algorithm. Our data show children with severe to profound SNHL should first be tested with a GJB2 screen, as opposed to those with milder SNHL, who should undergo imaging as the initial testing step. In patients with initially positive GJB2 or imaging screens, logistic regression analysis significantly predicted negative results on further testing. CONCLUSIONS: A stepwise diagnostic paradigm tailored to the level of the hearing loss in children with bilateral SNHL is more diagnostically efficient and cost effective than the more commonly used full, simultaneous testing approach. Laboratory investigation should not be routine but based on clinical history. 相似文献
37.
38.
39.
40.
Peter B. Arnold Chris A. Campbell George Rodeheaver Wyndell Merritt Raymond F. Morgan David B. Drake 《Hand (New York, N.Y.)》2009,4(3):302-307
The purpose of this study was to demonstrate that perivascularly applied botulinum toxin-A (BTX) increases the diameter of
treated blood vessels in a rat femoral vessel exposure model. Six adult Sprague–Dawley rats were used and bilateral femoral
artery and vein exposures were performed. Five units of BTX were applied to the experimental side and an equal volume of sterile
saline was applied to the control side. Digital images of the vessels were obtained at the following time points: pretreatment,
immediately posttreatment, and postoperative days (POD) 1, 14, and 28. Vessel diameters were equivalent at baseline and immediately
following application of BTX and saline. The BTX artery was significantly larger than the control artery on POD 1 and 14.
The BTX treated artery was significantly larger than all other vessels on POD 14 (p < 0.05) as well as all prior time points (p < 0.01). Direct perivascular application of BTX increases the diameter of rat femoral vessels as early as POD 1. The affect
is most robust on POD 14 where the artery was significantly larger than all other vessels at all time points. It is likely
that the increased diameter of blood vessels results in an increased blood flow across the area of dilation. Such an increase
in flow may serve to improve end-organ perfusion in microvascular procedures. 相似文献